Condiciones de salud que coliflor puede ayudar a apoyar.
Berberine has been studied in clinical trials for IBS and functional abdominal discomfort, showing significant reductions in abdominal discomfort scores when used alone or in combination with curcumin. A 2024 observational study (n=146 IBS patients) reported 47.2% improvement in abdominal discomfort with berberine/curcumin supplementation.
Berberine, an isoquinoline alkaloid from plants such as Goldenseal and Coptis chinensis, has documented in vitro antimicrobial activity against Staphylococcus aureus including MRSA, a primary abscess-causing pathogen. It has traditional use in Chinese and Indian medicine for infections. Mechanistic and synergistic antibiotic studies support its role, though clinical abscess-specific trials are absent.
Berberine, an isoquinoline alkaloid from Berberis species, has demonstrated antimicrobial activity against C. acnes, anti-inflammatory effects, and beneficial outcomes in acne patients, including those with PCOS-related hormonal acne. A 4-week RCT with 25 participants with moderate-to-severe acne tested Berberis vulgaris. In vitro studies show MIC values of 6.25–12.5 μg/mL against C. acnes strains.
Berberine demonstrably enhances the activity of key antioxidant enzymes (GSH, GPx, SOD, catalase) and reduces markers of oxidative stress (MDA, ROS) across experimental and clinical contexts. This activity underlies many of its protective effects in metabolic, cardiovascular, renal, and neurological disease models.
Berberine modulates appetite-related hormones—reducing fasting ghrelin and elevating GLP-1—and activates AMPK, which collectively suppress food intake signals. Clinical trials show significant reductions in body weight, BMI, and waist circumference. Direct measurement of subjective hunger remains an acknowledged research gap; effects on body composition are better documented than appetite per se.
Berberine activates AMPK and improves endothelial function, reduces LDL oxidation, and inhibits platelet aggregation and arterial smooth muscle proliferation. A 2021 RCT showed berberine reduced LDL oxidation by 40% and improved endothelial function in diabetic patients. PubMed-indexed reviews classify berberine among nutraceuticals with favorable metabolic and vascular effects.
Berberine, an isoquinoline alkaloid from Traditional Chinese Medicine plants, has multiple systematic reviews and meta-analyses supporting blood pressure reduction. It activates AMPK, improves endothelial function, and modulates the renin-angiotensin system. A 2015 meta-analysis confirmed antihypertensive effects alongside lipid and glucose improvements.
Berberine is one of the most clinically studied botanical compounds for blood sugar regulation. Multiple meta-analyses of RCTs in type 2 diabetes patients show significant reductions in fasting plasma glucose, postprandial glucose, and HbA1c. It activates AMPK and has been compared favorably to metformin in some trials.
Berberine, an isoquinoline alkaloid from plants including barberry and goldenseal, shows documented antifungal activity against multiple Candida species in vitro, including fluconazole-resistant strains. It disrupts Candida membranes, inhibits biofilm formation, and inhibits C. albicans adhesion to vaginal epithelial cells in clinical mechanistic studies. Preclinical evidence is extensive though human Candida-specific RCTs remain limited.
Berberine, a bright yellow isoquinoline alkaloid found in barberry, goldenseal, and Oregon grape, has documented antifungal activity against multiple Candida species in vitro by disrupting fungal mitochondrial function, inhibiting adhesion to host cells, and synergizing with azole drugs. Multiple in vitro studies confirm inhibition of Candida biofilm formation and interference with fungal glucose metabolism. It is widely used in Candida cleanse protocols.
Multiple meta-analyses of RCTs show berberine significantly reduces total cholesterol, LDL-C, and triglycerides in hyperlipidemic patients. A meta-analysis of 16 trials (2,147 patients) found reductions of 0.47 mmol/L total cholesterol and 0.38 mmol/L LDL-C. Its primary mechanism is upregulation of the hepatic LDL receptor. Typical studied doses range from 500–1,500 mg/day.
Berberine, an isoquinoline alkaloid with a long history in Traditional Chinese Medicine, has demonstrated anti-inflammatory activity in multiple randomized controlled trials and meta-analyses. It significantly reduces circulating levels of CRP, TNF-α, and IL-6 in human populations. Its primary mechanisms involve inhibition of the NF-κB signaling pathway and activation of AMPK, both of which suppress pro-inflammatory cytokine production.
Multiple RCTs and meta-analyses demonstrate that berberine significantly lowers LDL cholesterol, total cholesterol, and triglycerides while modestly raising HDL. It also improves endothelial function and vascular elasticity in clinical populations. Effects on blood pressure have been inconsistent across trials.
Berberine has demonstrated consistent neuroprotective effects in preclinical Alzheimer's disease models, reducing amyloid-beta deposition, tau phosphorylation, and neuroinflammation. Indirect clinical evidence exists through BBR's management of metabolic risk factors (diabetes, dyslipidemia, hypertension) that contribute to cognitive decline. Direct human cognitive endpoint trials are currently absent.
A 2024 meta-analysis of 10 RCTs (952 UC patients) found berberine combined with 5-ASA significantly improved clinical efficacy rate (RR=1.22), reduced disease activity index scores, and attenuated inflammatory markers. Berberine has been used in traditional Chinese medicine for centuries for gastrointestinal inflammatory conditions.
Berberine is an isoquinoline alkaloid with well-documented effects on intestinal motility, gut microbiota modulation, and antimicrobial activity against intestinal pathogens, supporting its use in colon-cleanse formulations. Clinical evidence from RCTs demonstrates its ability to modulate bowel function and reduce pathogenic gut bacteria. Used in both Traditional Chinese Medicine and modern clinical contexts for gastrointestinal health.
Berberine has documented antidepressant-like activity across preclinical models and limited clinical data. It modulates monoamine neurotransmitter systems, reduces neuroinflammation, and promotes hippocampal neurogenesis. One clinical RCT in IBS patients showed berberine hydrochloride improved depression scale scores.
Berberine is one of the best-studied natural antidiarrheal agents with multiple RCTs. A 1987 RCT in 165 adults showed 400 mg berberine sulfate significantly reduced stool volume in ETEC diarrhea. A 2015 RCT in 196 IBS-D patients found 400 mg/day berberine hydrochloride significantly reduced diarrhea frequency, abdominal pain, and urgency versus placebo. A 2020 systematic review of 38 RCTs (3948 participants) confirmed efficacy in both children and adults.
Berberine has been evaluated in multiple RCTs for improving fertility outcomes in women with PCOS, primarily by improving insulin sensitivity and reducing androgen levels. Meta-analyses show significant improvements in ovulation rate, endometrial thickness, and clinical pregnancy rate when combined with conventional treatment.
Berberine, a natural isoquinoline alkaloid from plants such as Coptis and Berberis, has demonstrated broad-spectrum antifungal activity against Candida albicans, Cryptococcus neoformans, and Trichophyton species in vitro, with MIC values of 64–128 µg/mL. In vivo studies show berberine promoted healing in guinea pigs infected with T. mentagrophytes. Its mechanism involves CYP51 inhibition (ergosterol biosynthesis) and fungal membrane disruption.
Berberine, an isoquinoline alkaloid from barberry, goldenseal, and coptis, reduces cholesterol gallstone formation by regulating bile acid metabolism and stimulating bile production. A 2025 ScienceDirect review specifically confirms this effect. Berberine also has documented hepatoprotective effects and modulates FXR-mediated bile acid synthesis pathways.
Berberine, an isoquinoline alkaloid from plants such as Coptis chinensis and Berberis vulgaris, has been studied for its effects on cholesterol and bile acid metabolism relevant to gallstone disease. A 2024 PubMed study (Biochem Biophys Res Commun) specifically conducted at a Center of Gallstone Disease found berberine alleviates cholesterol and bile acid metabolism disorders induced by high-cholesterol diet in mice. A ScienceDirect review (2025) notes berberine can reduce cholesterol gallstone formation by regulating bile acid metabolism.
Berberine, an isoquinoline alkaloid from plants such as barberry and goldenseal, has demonstrated antimicrobial activity against H. pylori and anti-inflammatory effects in H. pylori-induced chronic gastritis in animal models. A meta-analysis of RCTs found berberine combined with triple therapy increases H. pylori eradication rates and reduces adverse effects such as nausea and diarrhea.
Berberine, an isoquinoline alkaloid, has preclinical and emerging clinical evidence for glaucoma neuroprotection. It attenuates RGC excitotoxicity, neuroinflammation, and apoptosis via P2X7 and GABA-PKC-α pathways. A 2024–2025 PubMed-based review explicitly identifies berberine among synergistic neuroprotective agents for glaucoma.
Berberine has been shown in multiple in vitro and animal studies to stimulate GLP-1 secretion from intestinal L-cells via activation of bitter taste receptors (TAS2R38) in a PLC-dependent pathway. It also restores GLP-1 secretion in diet-induced obese mouse models by protecting colon enterocyte mitochondrial function. Human studies support its glucose-lowering effects partly attributed to GLP-1 modulation.
Berberine has documented anti-inflammatory activity against key periodontal pathogens and mediators in experimental models. It suppresses TNF-α, IL-1β, IL-17, RANKL, and matrix metalloproteinases involved in periodontal tissue destruction. Gut microbiota modulation by berberine may also attenuate estrogen-deficiency-related periodontal bone loss.
Berberine is an isoquinoline alkaloid that significantly modulates gut microbiota composition, promoting beneficial bacteria such as Bifidobacterium and Lactobacillus while suppressing pathogenic species. Multiple clinical and preclinical studies confirm its gut microbiome-mediated mechanisms in metabolic and inflammatory conditions, including type 2 diabetes and IBD.
Berberine reshapes gut microbiota composition, modulates enteroendocrine signaling (GLP-1, dopamine precursors), and reduces intestinal barrier permeability, with downstream effects on neuroinflammation and brain function. Clinical and preclinical data document BBR's dual action on both gut homeostasis and neural signaling via the microbiome-gut-brain axis.
Berberine is a plant alkaloid that activates AMPK (similar to metformin), targeting key aging pathways including mTOR inhibition, mitochondrial biogenesis, and gut microbiome modulation. Multiple RCTs demonstrate berberine's effects on reducing glucose, cholesterol, and inflammatory markers in adults — comparable to metformin, a candidate longevity drug. It extends lifespan in model organisms.
Berberine, an alkaloid from plants including Berberis and Coptis, activates AMPK and inhibits PCSK9, reducing body weight and waist circumference in clinical trials. A 2020 meta-analysis of 12 RCTs found berberine significantly decreased body weight (−2.07 kg), BMI, and waist circumference versus placebo. It also improves insulin sensitivity, supporting metabolic weight management.
Berberine, a plant alkaloid from Coptis chinensis and related herbs, has substantial clinical and trial-level evidence supporting multiple cardiovascular benefits, including lipid-lowering, antihypertensive, antiarrhythmic, and anti-atherosclerotic effects. Multiple systematic reviews and meta-analyses of RCTs confirm reductions in LDL-C, total cholesterol, triglycerides, and inflammatory markers relevant to cardiovascular disease. Evidence also supports benefits in heart failure and arrhythmia, though overall trial quality is variable and large, long-term RCTs remain limited.
Berberine is an isoquinoline alkaloid from plants such as Coptis chinensis with well-characterized antiarrhythmic electrophysiological actions, including potassium channel blockade, action potential prolongation, and effective refractory period extension. In 24–48-hour Holter monitoring of 100 patients with ventricular tachyarrhythmia, berberine produced ≥50% reduction in VPCs in 62% of patients. A retrospective study compared berberine vs amiodarone for paroxysmal AF (45 vs 43 patients), showing comparable conversion rates with improved echocardiographic parameters.
Berberine is an alkaloid from Coptis, Berberis, and goldenseal used in TCM for millennia. A meta-analysis of 37 RCTs (n=3,048 T2DM patients) found it significantly reduced fasting glucose, HbA1c, and 2-hour postprandial glucose. Its glucose-lowering effect is high-glucose-dependent, reducing excessive blood glucose without causing hypoglycemia when used alone.
Berberine has multiple clinical studies demonstrating benefit in IBS, particularly IBS-D. A 2024 observational clinical study (Nutrients, n=146 IBS patients) combining berberine with curcumin found 93.1% experienced symptom improvement or resolution. Berberine reduces gut inflammation, modulates microbiota, and suppresses visceral hypersensitivity via the gut-brain axis. It is among the most pharmacologically studied botanicals for IBS-D.
Berberine is an isoquinoline alkaloid found in several plants including Coptis chinensis and Berberis species with preclinical and emerging clinical evidence for IBD, particularly UC. It reduces NF-κB-driven colonic inflammation, reshapes gut microbiota, and has been used in traditional Chinese medicine for GI inflammatory conditions.
Berberine activates AMPK to improve insulin sensitivity and reduce insulin resistance, with multiple RCTs and meta-analyses in patients with metabolic syndrome and type 2 diabetes demonstrating significant reductions in HOMA-IR. A 2021 systematic review and meta-analysis of RCTs confirmed blood sugar-lowering and insulin resistance amelioration, with effects becoming more pronounced after more than 3 months of treatment. Clinical studies show reduced HOMA-IR and improved adipokine profiles in metabolic syndrome patients after 3 months of treatment.
Berberine is a bioactive isoquinoline alkaloid found in plants such as barberry and Coptis chinensis, used in TCM and Ayurveda for over 2,000 years. Modern research demonstrates significant renoprotective effects across multiple kidney disorders including diabetic nephropathy, renal fibrosis, ischemia-reperfusion injury, and nephrotoxicity. A 2025 systematic review and meta-analysis of 26 animal studies found berberine significantly lowered serum creatinine, BUN, TGF-β1, and fibrosis area in models of renal fibrosis.
Berberine is an isoquinoline alkaloid extracted from plants such as Goldenseal, Berberis, and Coptis chinensis with documented effects on intestinal barrier integrity. Studies show berberine upregulates occludin and ZO-1 tight junction proteins in prediabetic rats, increases mucin production, and modulates gut microbiota toward beneficial species. A 2025 PMC review classified berberine as a promising adjuvant therapy for IBS, IBD, and ulcerative colitis specifically via enhancement of intestinal epithelial barrier integrity.
A 2012 study in human preadipocytes and metabolic syndrome patients (3 months of berberine treatment) showed berberine inhibits adipocyte differentiation and significantly downregulates leptin mRNA expression and leptin secretion, alongside PPARγ2 and adiponectin gene expression. In vitro data using human omental preadipocytes confirm berberine's modulatory role on leptin as an adipokine.
Berberine, an isoquinoline alkaloid found in goldenseal, barberry, and Coptis, demonstrates hepatoprotective effects in animal models of CCl4-induced acute hepatotoxicity, significantly reducing ALT, AST, and liver oxidative damage. Clinical trial reviews confirm berberine reduces liver enzymes in NAFLD and liver disease. It also activates AMPK, reducing hepatic fat accumulation.
Berberine, an isoquinoline alkaloid found in goldenseal, barberry, and Coptis, was included in the 2023 University of Maryland review as one of 13 herbs with in vitro antimicrobial activity relevant to Lyme disease. It modulates gut microbiome dysbiosis and intestinal barrier function, both commonly disrupted in chronic Lyme. It has anti-inflammatory activity via NF-κB inhibition. No clinical trials exist specifically for Lyme disease.
Multiple randomized controlled trials and meta-analyses provide clinical evidence that berberine meaningfully improves several core components of metabolic syndrome, including elevated triglycerides, fasting plasma glucose, and waist circumference. Its primary mechanism involves activation of AMP-activated protein kinase (AMPK), which improves insulin sensitivity and lipid metabolism. Evidence does not yet support syndrome-level remission, and effects on blood pressure and HDL-cholesterol are less consistent.
Berberine has robust clinical and mechanistic evidence supporting its role in metabolic health, particularly glucose and lipid regulation. Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate significant reductions in fasting blood glucose, triglycerides, LDL-cholesterol, BMI, and waist circumference. Its primary mechanism involves activation of AMP-activated protein kinase (AMPK), a central regulator of cellular energy balance, alongside additional pathways modulating insulin sensitivity and lipid biosynthesis.
Berberine activates AMPK by mimicking a low-energy state (increasing AMP/ATP ratio via LKB1 signaling), thereby stimulating mitochondrial biogenesis via PGC-1α. It improves mitochondrial function in metabolic disease models and has been studied in clinical trials for type 2 diabetes and metabolic syndrome, showing effects on cellular energy metabolism.
Berberine (BBR), a plant alkaloid from traditional Chinese medicine herbs, has demonstrated anti-inflammatory activity against both acute and chronic pancreatitis in preclinical models. It inhibits JNK, NF-κB, and MAPK signaling, reducing serum amylase, lipase, TNF-α, IL-1β, and IL-6 in cerulein- and L-arginine-induced mouse models. A 2020 study showed berberine attenuates chronic pancreatitis fibrosis via AMPK-mediated inhibition of TGF-β1/Smad signaling.
Berberine has clinical trial evidence for Giardia lamblia treatment and in vitro evidence against Entamoeba histolytica and Trichomonas vaginalis. It was historically evaluated as a potential pharmaceutical antiparasitic drug and is one of the most rigorously studied natural antiparasitic compounds.
Berberine, an alkaloid from plants such as Coptis chinensis and Berberis, has been evaluated in multiple RCTs for PCOS. It activates AMPK similarly to metformin, improving insulin sensitivity, reducing fasting insulin, lowering testosterone, and supporting menstrual regularity in women with PCOS-associated insulin resistance.
Berberine, an isoquinoline alkaloid from Berberis and Coptis species, has demonstrated antiviral activity against influenza A (H1N1) in animal lung infection models, reducing viral titer and improving survival. It is a component of traditional Chinese medicine pneumonia treatment protocols referenced in China's COVID-19 Treatment Program. Mechanistic studies support its activity against pneumonia-associated pulmonary fibrosis via TNF-α, IL-6, and STAT3 pathways.
A 2020 Lancet Gastroenterology & Hepatology double-blind RCT (n=1,108) found berberine 0.3 g twice daily reduced colorectal adenoma recurrence from 47% to 36% (RR 0.77, p=0.001) over two years. A 6-year follow-up retrospective cohort confirmed persistent protective effects (34.7% vs. 52.1% recurrence). Berberine is also under active investigation for familial adenomatous polyposis.
Berberine is the primary active alkaloid in Mahonia aquifolium (Oregon grape) responsible for its anti-psoriatic effects. It suppresses lipoxygenase, reduces T-cell infiltration in psoriatic lesions, inhibits cyclooxygenase, and downregulates IL-8 and prostaglandin E2. Clinical trials of Mahonia aquifolium preparations have demonstrated efficacy in plaque psoriasis.
Berberine, a plant alkaloid from Berberis, Coptis, and related genera, has been studied head-to-head against rifaximin for SIBO. A 2014 study (Global Advances in Health and Medicine) found herbal protocols containing berberine achieved 46% breath-test normalization versus 34% with rifaximin. A PMC-published RCT protocol (BRIEF-SIBO study) directly evaluated berberine as a single agent against rifaximin in SIBO patients, documenting its modulation of gut microbiota composition and reduction of pathogenic bacteria.
Berberine is an isoquinoline alkaloid from berberis, coptis, and related plants that activates AMPK and the AMPK/SIRT1 pathway to promote white adipose tissue remodeling and thermogenesis by increasing UCP-1 expression. Multiple RCTs confirm anti-obesity effects. A 2021 PMC study mechanistically confirmed berberine promotes thermogenesis via AMPK/SIRT1-PPARγ deacetylation.
Berberine, the primary alkaloid of Goldenseal and Barberry, inhibits adhesion of Streptococcus to the throat lining—a key mechanism in bacterial tonsillitis. In vitro studies confirm antibacterial activity against Streptococcus pyogenes and Staphylococcus. It is cited by naturopathic practitioners for tonsillitis management, though dedicated clinical tonsillitis RCTs are lacking.
Berberine, an alkaloid from plants such as goldenseal and Coptis chinensis, has been shown in multiple meta-analyses of RCTs to significantly reduce triglycerides. A 2025 meta-analysis confirmed berberine significantly reduces TG as a component of its broad metabolic effects. It is widely used clinically in China for dyslipidemia.
Berberine, an isoquinoline alkaloid found in multiple plants, has demonstrated anti-H. pylori activity and antiulcer effects in preclinical studies. It inhibits H. pylori adhesion to gastric cells, modulates gut flora, and reduces gastric mucosal inflammation. Multiple authoritative sources identify berberine as a candidate for adjunctive H. pylori management relevant to peptic ulcer.
Berberine is a plant alkaloid (from goldenseal, barberry, and related species) with documented anti-adhesive and antimicrobial effects relevant to urinary flora. It disrupts bacterial membranes and may inhibit E. coli adhesion to bladder epithelium. Clinical studies combining berberine with arbutin and D-mannose showed significantly reduced bacterial load in urinary samples and lower recurrence of cystitis compared to proanthocyanidin-only treatment. Research also suggests berberine acts as a prebiotic indirectly supporting beneficial gut bacteria.
Berberine, the primary alkaloid of Goldenseal, barberry, and Oregon grape, demonstrates direct antibacterial activity against uropathogens including drug-resistant E. coli in vitro. It inhibits bacterial adhesion to uroepithelial cells and disrupts biofilm formation. It is identified as the key antimicrobial compound in goldenseal for UTI, with activity against a broad spectrum of bacteria, viruses, fungi, and protozoa.
Berberine is an isoquinoline alkaloid from berberis, goldenseal, and other plants with documented antiviral activity against influenza, HSV, HBV, HIV, SARS-CoV-2, RSV, and dengue viruses. It inhibits viral entry and replication and modulates innate immune antiviral signaling. Extensive in vitro evidence is supplemented by limited clinical data.
Berberine is an isoquinoline alkaloid from plants including Berberis, Goldenseal, and Coptis with documented hepatoprotective and gut microbiome-modulating properties. It supports liver detoxification via anti-inflammatory and antioxidant mechanisms, and modulates bile acid metabolism and gut flora balance as part of whole-body cleanse formulations.
Berberine promotes wound healing by modulating inflammation, reducing oxidative stress, and stimulating epithelial cell migration and proliferation. Animal and cell-model studies (including radiation-induced skin injury) confirm accelerated wound closure. Human clinical wound healing trial data remain limited.
Berberine-containing plants such as Coptis chinensis (Huang Lian) and Berberis species have been used for millennia in Traditional Chinese Medicine and Ayurveda to treat febrile and 'heat' conditions. This use is documented in classical TCM texts but lacks dedicated modern human clinical trial evidence for antipyretic effect.
Berberine, the principal alkaloid in goldenseal, barberry, and Oregon grape, has documented in vitro antimicrobial activity against common sinus pathogens. It is used in Traditional Chinese Medicine (Coptis chinensis) for respiratory infections. Specific clinical trials for sinusitis are absent; support is primarily traditional and mechanistic.
Berberine, an isoquinoline alkaloid found in goldenseal, barberry, and Coptis, has demonstrated anti-adhesive, antibacterial, and anti-biofilm activity against E. coli and other uropathogens in laboratory studies. It has been used in Chinese and Ayurvedic medicine for urinary tract conditions historically. Robust clinical UTI-specific trials are lacking, but in vitro evidence of inhibiting E. coli adhesion to bladder epithelium is consistent.
Volver